B. Riley analyst Anderson Schock initiated coverage of Exagen (XGN) with a Buy rating and $15 price target reflecting 50% potential upside. Exagen is a diagnostics company that develops blood tests to help rheumatologists diagnose autoimmune diseases, the analyst tells investors in a research note. The firm believes the company’s AVISE CTD is well positioned to become the “gold standard” for both lupus and rheumatoid arthritis diagnosis.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen’s Legal Challenges: Potential Risks to Financial Stability and Market Position
- Exagen Inc. Reports Record Revenue Amidst Growth Challenges
- Exagen price target raised to $10 from $7 at Cantor Fitzgerald
- Exagen price target raised to $11 from $8 at Canaccord
- Exagen’s Strong Q2 Performance and Growth Strategy Justify Buy Rating